Single cells

Encapsulating Biology
Transforming Discovery

Our novel research and integrated instruments and collaborative research services enable the rapid engineering, screening and characterisation of single cells and their biological products. These cells are subsequently useful in research, biotherapeutics, bioproduction, cell therapy, drug discovery and diagnostics.

If you’re searching for rare and valuable variants within large cell populations, or wish to engineer them, we can help you do it faster, more cost-effectively and with a greater chance of success.

The Fast and Effective Engineering and Screening of Single Cells for Research and Development Applications

With flexible, future-proofed technologies we boost assay throughput and sensitivity, reduce consumable usage and optimise discovery, development and bioproduction across a broad range of applications.

Biopharmaceuticals and antibody production

Biopharmaceutical Discovery and Development

Increase the throughput and speed of your R&D pipeline. Better characterise biotherapeutic products. Carry out effective cell sorting and retrieval – and find those ‘rare’ variants.

Read More

Synthetic biology

Bioproduction and Synthetic Biology

Rapidly screen large libraries to sort through diverse populations of bacteria, yeast, hybridomas and transformed cells to find the best clones with the relevant phenotype.

Read More

Cell therapy engineering, analysis and isolation

Cell Therapy Engineering and Genome Editing

Use primary cells or precision engineer or transform, analyse and select cells for therapeutic applications, such as using engineered T-Cells for cell therapy, or novel research studies.

Read More

Drug discovery and biotherapeutics

Single Cell Disease Research

Carry out in-depth studies into infectious diseases, cancer and autoimmune disease through the effective compartmentalisation and analysis of single cells from disease-related samples.

Read More

Metagenomic analyses


Use our systems to carry out comprehensive metagenomic analyses that probe deeper into complex conditions, such as metabolic disorders and poorly defined diseases.

Read More

Single cell diagnostics

Single Cell Diagnostics and Prognostics

Our technology is an effective tool for purifying complex clinical samples and analysing single cells to improve patient diagnosis and better predict prognosis.

Read More

Lorem Ipsum Dolor Sit Amet

Lorem ipsum dolor sit amet, sit soluta aliquam at, minim virtute eu per. Nec ne duis reque iriure, et tota novum facilisi usu, principes constituam qui ea. Mel aperiri vocibus cu, no eos saperet prodesset. Quo populo disputando ut. Per suas complectitur no, vel in viris quando qualisque. Et wisi graeco habemus eam, in nulla assentior mnesarchum mel, ne his nominavi partiendo.

Soluta deterruisset nam ei, esse sanctus consulatu ad pro. Legere graece vis ne, has ut ludus facilisi. Ea eos principes assentior, mei nibh maiorum minimum ad. His id nibh dolore, pro percipitur consequuntur cu, eos consequat adipiscing id.


Our technology makes it possible to screen billions of cells and provides you with the best chance of finding that rare and valuable variant.

How do we do this? With microfluidic technology that allows the ultra-high throughput analysis of isolated single cells in miniaturised (pL to nL) volumes, picodroplets.

We offer a number of systems, from fully automated and integrated solutions designed for ‘plug and play’ use, through to flexible research instruments and customised research services for use in laboratories with more specialised needs. Our range of cost-effective consumables is specifically designed to work harmoniously with our instruments, providing significant time, cost and energy savings when used together.

Our technology and expertise is applied with our novel workflows to aid the discovery and development of therapeutics from single cells. Whether it’s for short research projects, technology development programs or partnerships, we provide a range of specialist collaborative services to suit your needs. Together we can reduce the cost and complexity of your research, and increase the speed of your discoveries.

Sphere Fluidics expands Cyto-Mine sales team and distribution in US, Europe and Asia.

Cambridge, UK, 30 January 2018: Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, has today announced the expansion of its international commercial operations. The Company is expanding its direct sales and support activity in North America, having recently opened a sales and support operation in New Jersey, and has established a network of distributors in Europe and the Far East to support the launch of its integrated Cyto-Mine Single Cell Analysis System.

Cyto-Mine is the first high-throughput instrument to integrate and automate several vital processes routinely used in the biopharmaceutical discovery and development workflows, including single cell analysis, sorting, imaging and dispensing into individual wells of microplates. Cyto-Mine utilises Sphere Fluidics’ proprietary picodroplet technology and microfluidics to process up to 10 million heterogeneous mammalian cells in less than a day. Its unique workflow enables selective screening of single cells to identify, isolate and dispense rare lead candidates, and provides assurance of monoclonality to aid FDA approval.

Sphere Fluidics has recently increased Cyto-Mine sales and support activities at its new US facility.

Mr Craig Cardella, Sales and Marketing Director, North America at Sphere Fluidics, stated: “We have recently established an East Coast sales, service and demonstration laboratory facility in a new facility at Monmouth Junction, NJ, which will be further supported with other new hires”.

The Company has also expanded its distribution to cover all major markets in Europe and Asia, including Japan and China.

Dr Frank Craig, CEO and Director at Sphere Fluidics, commented: Single cell analysis is a strongly growing area for both biopharmaceutical and academic markets. Cyto-Mine offers significant time and cost savings for customers working in biologics discovery and cell line development, and will help to improve efficiency by increasing throughput and isolating single cells of high commercial potential.

Dr Rob Marchmont, Sales and Marketing Director at Sphere Fluidics, commented: Increasing our international sales activities represents a critical step towards becoming a global supplier of leading-edge instruments in the area of single cell analysis and has the potential to transform Sphere Fluidics from an R&D services provider to a fully commercial company.

Cyto-Mine will be on display in San Diego, CA at SLAS 2018 from 3rd to 7th February 2018 (Booth #1940) and in San Francisco, CA at The Molecular Medicine Tri Conference from 11th to 16th February 2018 (Booth #737).

For more information on the Cyto-Mine, please visit:

For a list of distributors, visit:

No events currently scheduled